Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nurix Therapeutics, Inc. (NRIX : NSDQ)
 
 • Company Description   
Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California.

Number of Employees: 286

 
 • Price / Volume Information   
Yesterday's Closing Price: $12.67 Daily Weekly Monthly
20 Day Moving Average: 843,336 shares
Shares Outstanding: 76.45 (millions)
Market Capitalization: $968.61 (millions)
Beta: 2.15
52 Week High: $29.56
52 Week Low: $8.18
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 5.94% 1.97%
12 Week 23.73% 4.07%
Year To Date -32.75% -37.02%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1700 OWENS STREET SUITE 205
-
SAN FRANCISCO,CA 94158
USA
ph: 415-660-5320
fax: -
ir@nurixtx.com http://www.nurixtx.com
 
 • General Corporate Information   
Officers
Arthur T. Sands - Chief Executive Officer; President and Director
Julia P. Gregory - Chairman
Hans van Houte - Chief Financial Officer
Anil Kapur - Director
Lori A. Kunkel - Director

Peer Information
Nurix Therapeutics, Inc. (CORR.)
Nurix Therapeutics, Inc. (RSPI)
Nurix Therapeutics, Inc. (CGXP)
Nurix Therapeutics, Inc. (BGEN)
Nurix Therapeutics, Inc. (GTBP)
Nurix Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 67080M103
SIC: 2834
Fiscal Year
Fiscal Year End: November
Last Reported Quarter: 05/01/25
Next Expected EPS Date: 10/10/25
Share - Related Items
Shares Outstanding: 76.45
Most Recent Split Date: (:1)
Beta: 2.15
Market Capitalization: $968.61 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.79 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.97 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 10/10/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.16
Price/Cash Flow: -
Price / Sales: 10.96
EPS Growth
vs. Year Ago Period: 26.76%
vs. Previous Quarter: 22.39%
Sales Growth
vs. Year Ago Period: 264.34%
vs. Previous Quarter: 138.75%
ROE
05/31/25 - -45.26
02/28/25 - -47.49
11/30/24 - -53.65
ROA
05/31/25 - -34.71
02/28/25 - -36.10
11/30/24 - -38.59
Current Ratio
05/31/25 - 6.82
02/28/25 - 6.26
11/30/24 - 6.46
Quick Ratio
05/31/25 - -
02/28/25 - 6.26
11/30/24 - 6.46
Operating Margin
05/31/25 - -234.57
02/28/25 - -369.40
11/30/24 - -354.85
Net Margin
05/31/25 - -234.57
02/28/25 - -369.40
11/30/24 - -354.85
Pre-Tax Margin
05/31/25 - -233.61
02/28/25 - -369.08
11/30/24 - -354.36
Book Value
05/31/25 - 5.85
02/28/25 - 6.31
11/30/24 - 7.44
Inventory Turnover
05/31/25 - -
02/28/25 - -
11/30/24 - -
Debt-to-Equity
05/31/25 - 0.00
02/28/25 - 0.00
11/30/24 - 0.00
Debt-to-Capital
05/31/25 - 0.00
02/28/25 - 0.00
11/30/24 - 0.00
 

Powered by Zacks Investment Research ©